Take one transaction. Apply two different, equally compliant accounting treatments. Watch the investment thesis change.
A company acquires a technology platform for Rs 200 crore. Under one purchase price allocation, the majority is assigned to goodwill (Rs 150 crore goodwill, Rs 50 crore identified intangibles with five-year useful lives). Under another allocation, more is assigned to identified intangibles with longer lives (Rs 80 crore goodwill, Rs 120 crore intangibles amortised over 15 years).
The economic transaction is identical. The cash outflow is identical. The business acquired is identical. The financial statement impact differs materially.
Under the first treatment: higher goodwill (no amortisation, only annual impairment testing), lower intangible amortisation charge (Rs 10 crore per year for five years), higher reported EBITDA and net profit during the first five years, but a larger balance sheet item exposed to impairment risk thereafter.
Under the second treatment: lower goodwill, higher intangible amortisation (Rs 8 crore per year for 15 years), lower reported EBITDA and net profit, but a balance sheet that better reflects the finite life of the acquired assets and carries less impairment risk.
An investor using EBITDA as a valuation metric would value the company more highly under the first treatment. An investor using free cash flow would value it identically under both. An investor focused on balance sheet quality would prefer the second.
The accounting did not change the economics. It changed how investors perceive the economics. And in capital markets, perception determines valuation.
The Pattern Across Accounting Choices
This pattern repeats across every significant accounting judgment.
Capitalisation vs expensing: Rs 20 crore of development cost capitalised as an intangible asset produces a balance sheet that is Rs 20 crore larger and a P&L that is Rs 20 crore better than if the same cost were expensed. The R&D investment is identical.
Depreciation: An asset depreciated over 10 years produces Rs 10 crore of annual depreciation. The same asset depreciated over 15 years produces Rs 6.67 crore. The difference, Rs 3.33 crore per year, flows directly to reported profit. The asset is the same. The economic consumption may be the same. The reported profit differs.
Revenue recognition: A contract with variable consideration can produce different revenue figures depending on whether management estimates the variable component at the expected value or the most likely amount. Both methods are compliant with Ind AS 115. They can produce materially different revenue in the period.
Provisions: A litigation provision estimated at Rs 15 crore by one methodology and Rs 25 crore by another changes reported profit by Rs 10 crore. The litigation risk has not changed. The measurement of the risk has.
The Board’s Role
In Northrop Management financial reporting advisory work, we evaluate significant transactions not only for their economic impact but for the range of accounting treatments available and the financial statement consequences of each.
The board should understand, for every significant accounting choice, what the range of compliant treatments is, where the company’s chosen treatment sits within that range, and how the choice affects the metrics investors use to value the company. This understanding does not require the board to second-guess every judgment. It requires the board to know which judgments have material consequences and whether those consequences have been considered.
Ashish Chaudhary, frames the principle directly: “Accounting does not change reality. It changes how reality is presented. And in capital markets, the presentation determines valuation, access to capital and cost of capital. A board that does not understand the presentation choices available has delegated a consequential decision to the finance team without knowing it.”
Questions for the Boardroom
- For our most significant accounting judgment (PPA, capitalisation, revenue recognition, provisioning), what is the range of compliant treatments and where does our chosen treatment sit within it?
- How would our reported EBITDA, net profit and ROIC change if we chose the treatment at the other end of the range?
- Do we understand how our accounting choices affect the metrics investors use to value us?
- Have we made any accounting choice in the last three years that materially changed how our performance appears without changing the underlying economics?
- If an analyst compared our accounting policies to our peers’ policies for the same economic transactions, would they find differences that explain reported performance differences?
Closing Implication
The investment thesis is built on numbers. The numbers are shaped by accounting choices. The choices are made within a range of compliant treatments, each producing a different version of the same economic event. The board that understands the range governs with full information. The board that does not understand it has not understood the numbers.
